



Universitat de Lleida

Document downloaded from:

<http://hdl.handle.net/10459.1/65724>

The final publication is available at:

<https://doi.org/10.1002/mnfr.201800623>

Copyright

(c) WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, 2018



Validation of dried blood spot cards to determine apple phenolic metabolites in human blood and plasma after an acute intake of red-fleshed apple snack

Journal:	<i>Molecular Nutrition and Food Research</i>
Manuscript ID	Draft
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Yuste, Silvia; Universitat de Lleida Escola Tecnica Superior d'Enginyeria Agraria, Food Technology Department Macià, Alba; Universitat de Lleida Escola Tecnica Superior d'Enginyeria Agraria, Food Technology Department Ludwig, Iziar; Universitat de Lleida Escola Tecnica Superior d'Enginyeria Agraria, Food Technology Department Romero, Maria Paz; Universitat de Lleida Escola Tecnica Superior d'Enginyeria Agraria, Food Technology Department Fernández-Castillejo, Sara; Universitat Rovira i Virgili Catalán Santos, Úrsula; Universitat Rovira i Virgili Facultat de Medicina I Ciències de la Salut Motilva, María José; Universitat de Lleida , Food Department Rubió, Laura; Universitat de Lleida Escola Tecnica Superior d'Enginyeria Agraria, Food Technology Department
Keywords:	dried blood spot cards, plasma, phenolic metabolites, tandem MS, whole blood

SCHOLARONE™
Manuscripts

1 1 **Validation of dried blood spot cards to determine apple phenolic metabolites in human**
2
3 2 **blood and plasma after an acute intake of red-fleshed apple snack**
4
5 3
6

7 4 Silvia Yuste¹⁺, Alba Macià¹⁺, Iziar Ludwig¹, Maria-Paz Romero¹, Sara Fernández-Castillejo²,
8
9 5 Úrsula Catalán^{2,3}, Maria-Jose Motilva¹, Laura Rubió^{1*}
10
11

12 6
13
14 7 ¹ Food Technology Department, Agrotecnio Research Center, University of Lleida, Av/
15
16 8 Alcalde Rovira Roure 191, 25198-Lleida, Spain.
17

18 9 ² Universitat Rovira i Virgili, Facultat de Medicina i Ciències de la Salut, Functional
19
20 10 Nutrition, Oxidation, and Cardiovascular Diseases Group (NFOC-Salut), Reus, Spain.
21
22

23 11 ³ Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
24
25

26 12
27 13 ⁺ SY and AM contributed equally to the study.
28

29 14 * Corresponding author: Laura Rubió
30
31

32 15

33 16

34 17

35 18

36 19

37 20

38 21

39 22

40 23

41 24

42 25

43 26

44 27

Abstract

The application of dried blood spot (DBS) cards for dietary polyphenol pharmacokinetics in human blood has been poorly studied. An analytical method based on blood sampling with DBS cards combined with liquid chromatography coupled to tandem mass spectrometry has been developed and validated. To test the method validation, the phenolic metabolites were determined in human blood and plasma obtained after an acute intake of a red-fleshed apple snack in ten volunteers. Capillary blood by finger prick was compared to venous blood by venipuncture and whole blood was also compared to their corresponding venous plasma samples. Moreover, the venous plasma results using DBS cards were compared to those obtained by microElution solid-phase extraction (μ SPE). The main phenolic metabolites detected in blood and plasma samples were phloretin glucuronide, dihydroxyphenylpropionic acid sulphate, (methyl) catechol sulphate, catechol glucuronide and hydroxyphenyl- γ -valerolactone glucuronide as phase II conjugated and colonic metabolites. No significant differences were observed between capillary blood, venous blood and plasma samples using DBS, and neither between plasma samples analyzed by DBS or μ SPE. In conclusion, finger-prick blood sampling based on DBS appears to be a suitable alternative to the classic invasive venipuncture for the determination of circulating phenolic metabolites in nutritional postprandial studies.

Key words: dried blood spot cards, plasma, phenolic metabolites, tandem MS, whole blood

1. Introduction

Over recent years, there has been a large increase in the reporting of the use of dried blood spot (DBS) cards for therapeutic drug monitoring and quantitative biomarker assessment [1]. It has established itself as an innovative sampling technique where wet blood is spotted onto absorbent paper offering several potential benefits inherent to the technique, namely being less invasive than venous blood sampling, simplified blood sample collection and convenient sample storage [2]. The small volume of the blood sample and complexity of the matrix leads to analytical challenges in terms of sensitivity and selectivity which could have hampered the attractiveness of DBS cards. However, these limitations have been overcome by the significant improvement in the sensitivity of current liquid chromatography coupled to mass spectrometry (MS) instruments [1].

One area that has received less attention in the application of DBS cards as a blood collection technique concerns the evaluation of the pharmacokinetic parameters of food bioactive compounds, such as dietary polyphenols. Red blood cells, particularly erythrocytes, represent a significant compartment for distribution of drugs and endogenous biological metabolites and it has been suggested that these could be factored into pharmacokinetic and pharmacodynamic evaluations [3]. In fact, the binding of low concentrations of polyphenols to red blood cells has been previously reported [4-6]. Therefore, the possibility of direct blood sampling as the mainstay matrix instead of plasma might yield valuable information in *in vivo* bioavailability studies of dietary polyphenols.

Moreover, as DBS sampling is based on arterial capillary blood and some amount of interstitial fluid, the concentrations of circulating metabolites could potentially be different from venous blood. As these differences are dependent on the characteristics of particular drugs or diet xenobiotics, case-to-case evaluation is necessary to validate the method [7].

The analysis of phenolic metabolites in human blood was successfully applied in our previous studies after the acute intake of strawberry tree fruit [8], and an olive oil phenolic

1 75 extract [9]. In these studies, the blood was collected with micro-capillary blood collection
2
3 76 tubes, and a fixed volume of blood was spotted onto the filter paper with a micropipette.
4
5 77 However, a simplified strategy to quantify the phenolic metabolites by placing blood directly
6
7 78 onto the DBS cards has not been tested.
8
9

10 79 The aim of the present study was to develop and validate an analytical method based
11
12 80 on the combination of DBS cards as simple sampling procedure combined with a sensitive
13
14 81 chromatographic method (ultra-performance liquid chromatography coupled to tandem mass
15
16 82 spectrometry, UPLC-MS/MS) to analyze the main circulating phenolic metabolites in blood
17
18 83 and plasma after a human acute intake of a red-fleshed apple snack. The method was
19
20 84 validated in terms of linearity, reproducibility, method detection limits, method quantification
21
22 85 limits, accuracy and matrix effects.
23
24

25 86 Specifically, the study focuses on three issues: 1) the comparison of venous and capillary
26
27 87 blood sampling, 2) the assessment of the differences between plasma and whole blood, and 3)
28
29 88 the comparison of DBS cards and microElution solid-phase extraction (μ SPE), as the most
30
31 89 common method for the analysis of circulating phenolic metabolites in plasma.
32
33
34
35

36 91 **2. Materials and methods**

37 92 **2.1. Chemicals and reagents**

38
39
40 93 The commercial standard 3-(2',4'-dihydroxyphenyl)propionic acid was purchased from
41
42 94 Fluka (Buchs, Switzerland); epicatechin was from Sigma-Aldrich (St Louis, MO, USA) and
43
44 95 phloretin-2'-*O*-glucoside from Extrasynthese (Genay, France). Catechol-4-*O*-sulphate and 4-
45
46 96 methyl catechol sulphate were supplied by Dr. Claudia N. Santos (IBET, Oeiras, Portugal)
47
48 97 and synthesized according to the method reported by Pimpao *et al.* [10]. Stock solutions of
49
50 98 individual phenolic standard compounds were prepared by dissolving each compound in
51
52 99 methanol at a concentration of 1000 mg/L, and storing these in dark flasks at 4°C.
53
54
55
56
57
58
59
60

1 100 Acetonitrile (HPLC-grade) was from Romil (Tecknokroma, Barcelona, Spain).
2
3 101 Methanol (HPLC-grade), phosphoric acid (85 %) and glacial acetic acid (99.8 %) were from
4
5 102 Scharlau S.L. (Barcelona, Spain). Ultrapure water was obtained from a Milli-Q water
6
7 103 purification system (Millipore Corp., Bedford, MA, USA).
8
9
10 104

11 105 **2.2. Red-fleshed apple snack**

12
13
14 106 The red-fleshed apple variety used was 'Redlove Era' and was provided by Nufri
15
16 107 (Mollerussa, Lleida, Spain) and planted in the experimental plot at La Rasa (Soria, Spain).
17
18 108 Immediately after the fresh apples arrived at the laboratory, they were washed, wiped with
19
20 109 paper towels and cut into 1 cm cubes. The apple cubes were frozen in liquid nitrogen and
21
22 110 freeze-drying was then performed with a first drying at 0.6 bar with a temperature ramp of -20
23
24 111 to 0°C for 25 hours, followed by a second complete vacuum drying with a temperature ramp
25
26 112 of 0 to 20°C for 40 hours (Lyophilizer TELSTAR Lyobeta 15, Terrassa, Spain). After that,
27
28 113 the apple snack was preserved in a desiccator protected from light.
29
30

31 114 For the quantification of phenolic compounds, 0.1 g of crushed apple snack was
32
33 115 analyzed according to our previous study [11]. The phenolic dose ingested through a portion
34
35 116 of 80 g of red-fleshed apple snack is shown in **Table 1**, where 46% were phenolic acids
36
37 117 (mainly chlorogenic acid), 22% were anthocyanins (mainly cyanidin-3-*O*-galactoside), 17 %
38
39 118 dihydrochalcones (mainly phloretin glucoside derivatives), 9% flavonols (mainly quercetin
40
41 119 derivatives), 7% flavan-3-ols (mainly epicatechin and dimer), and 0.2% flavanone (mainly
42
43 120 eriodictyol derivatives).
44
45

46 121

47 122 **2.3. Study design and blood sample collection**

48
49
50 123 The protocol of the study was approved by the Ethical Committee of Human Clinical
51
52 124 Research at the Arnau Vilanova University Hospital, Lleida, Spain (Approval Number:
53
54 125 13/2016). Ten healthy volunteers (five females and five males, mean age 37.3 ± 8.4 years)
55
56
57
58
59
60

1 126 were recruited and exclusion criteria were age < 25 or > 50 years, body mass index <18.5 or
2
3 127 >24.9 kg/m², pregnancy or lactation, any chronic medication, any antibiotic treatment during
4
5 128 the 4 months prior to the study, cigarette smoking, alcohol intake > 80 g/day and use of dietary
6
7 129 supplements. Subjects were asked to avoid the consumption of polyphenol-rich foods (e.g.,
8
9 130 coffee, fruit, vegetables, dark chocolate, green tea and red wine) for the 3 days prior to the
10
11 131 study. On the day of the study, the participants were invited to eat a portion of 80 g of red-
12
13 132 fleshed apple snack after fasting overnight. Capillary blood, venous blood and plasma
14
15 133 samples were obtained at the baseline and at different time points after consumption of the
16
17 134 apple snack (0 to 24 h). During this period, the participants avoided the consumption of
18
19 135 polyphenol-rich foods. Capillary blood was obtained by finger-pricking and blood drops were
20
21 136 directly applied to DBS cards at 0, 0.5, 1, 2, 4, 6, 12 and 24 h. Venous blood was collected by
22
23 137 venipuncture at 0, 0.5, 1, 2, 4, 6, and 24 h in 6 mL Vacutainer™ tubes (Becton, Dickinson and
24
25 138 Company, Franklin Lakes, NJ, USA) containing ethylene-diaminetetraacetic acid (EDTA) as
26
27 139 an anticoagulant. To obtain plasma samples, the blood tubes were centrifuged at 8784 g for 15
28
29 140 min (Hettich, Tuttlingen, Germany). The blood and plasma samples were aliquoted and stored
30
31 141 at -80 °C until further processing.
32
33
34
35
36
37

38 143 **2.4. Blood and plasma samples pre-treatment**

39 144 *2.4.1. DBS cards*

40
41
42 145 Capillary blood samples were obtained by pricking the volunteers' fingers with
43
44 146 disposable lancets (Unistik®, Owen Mumford Ltd, Woodstock, UK) and collected on FTA®
45
46 147 DMPK-A cards (DBS filter paper) (GB Healthcare, Buckinghamshire, UK). The first droplet
47
48 148 was discarded, since the initial flow from the 'prick' can be contaminated with interstitial
49
50 149 fluid, and good practice warrants discarding this first drop. After that, blood droplets were
51
52 150 directly spotted on to two pre-marked circles on the filter papers until they were completely
53
54 151 soaked, while avoiding direct contact between the finger and the card. Venous blood obtained
55
56
57
58
59
60

1 152 by venipuncture and the corresponding plasma samples were also applied to DBS cards. 30
2
3 153 μL of venous blood or plasma was defined as the exact volume to completely fill each pre-
4
5 154 marked circle. The pre-treatment procedure is depicted in **Figure 1A**.
6

7 155 In order to dry the spotted cards, they were maintained in the dark at room temperature
8
9 156 for 2 h. Afterwards, in order to extract and pre-concentrate the target compounds, the whole
10
11 157 surface of two blood or plasma-soaked circles were punched out using a 3-mm diameter
12
13 158 Harris Uni-Core punch and a Cutting Mat (Whatman Inc., Sanford, ME, USA). Different
14
15 159 conditions were tested for extracting the analytes, and the optimal conditions appeared to be
16
17 160 150 μL of methanol/Milli-Q water (50:50, v/v) as the elution solvent, vortexed for 20 min and
18
19 161 centrifuged at 8784 g for 10 min at room temperature. The supernatant was filtered with 0.22
20
21 162 μL Nylon 96-well filter microplate (Agilent technologies, Santa Clara, CA, USA), and 7.5 μL
22
23 163 of the filtered solution was injected into the chromatographic system.
24
25

26 164 2.4.2. μSPE cartridges

27 165 Venous plasma samples were also analyzed by $\mu\text{Elution}$ solid-phase extraction (μSPE)
28
29 166 based on our previous studies [12,13]. OASIS HLB $\mu\text{Elution}$ plates 30 μm (Waters, Milford,
30
31 167 MA, USA) were used. Briefly, the micro-cartridges were activated with 250 μL of methanol
32
33 168 and equilibrated with 250 μL of 0.2% acetic acid. 350 μL of venous plasma and 350 μL of 4
34
35 169 % phosphoric acid were centrifuged at 8784 g for 10 min at 4°C, and the supernatant was
36
37 170 loaded into the micro-cartridge. The loaded micro-cartridges were cleaned-up with 200 μL of
38
39 171 Milli-Q water and 200 μL of 0.2% acetic acid. Then, the retained compounds were then eluted
40
41 172 with 2 x 50 μL of methanol. 2.5 μL of the eluted solution was directly injected into the
42
43 173 chromatographic system (**Figure 1B**).
44
45

46 174

47 175 **2.5. Phenolic metabolites analysis by liquid chromatography coupled to tandem mass** 48 49 176 **spectrometry (UPLC-MS/MS)** 50

177 The phenolic compounds and their generated metabolites were determined in blood and
178 plasma samples by AcQuity Ultra-Performance™ liquid chromatography (UPLC) coupled to
179 a triple quadrupole detector (TQD) mass spectrometer (Waters, Milford). The analytical
180 column was an AcQuity BEH C₁₈ column (100 mm × 2.1 mm i.d., 1.7 μm,) equipped with a
181 VanGuard™ Pre-Column AcQuity BEH C₁₈ (2.1 × 5 mm, 1.7 μm), also from Waters. During
182 the analysis, the column was kept at 30 °C, and the flow rate was 0.3 mL min⁻¹. The mobile
183 phase and elution gradient were the same as those reported in our previous studies [8,11].

184 Tandem MS analyses were carried out on a triple quadrupole detector (TQD) mass
185 spectrometer (Waters, Milford, MA, USA) equipped with a Z-spray electrospray interface
186 (ESI). Ionization was achieved using the electrospray interface operating in the negative mode
187 [M-H]⁻ and the data were acquired through selected reaction monitoring (SRM). The
188 ionization source parameters were the same as the ones reported in our previous studies
189 [8,11].

190 Two SRM transitions were selected, the most sensitive one was used for quantification,
191 and the second for confirmation purposes. **Supplementary Table 1** shows the SRM transition
192 for quantification and identification, as well as the cone voltage and collision energy for each
193 phenolic metabolite. The dwell time established for each transition was 30 ms. Data
194 acquisition was carried out with the MassLynx 4.1 software. Due to the lack of commercial
195 standards of phenolic metabolites, some of these compounds were tentatively quantified by
196 using the calibration curve of their native compound or another phenolic compound with a
197 similar structure. Phloretin glucuronide was tentatively quantified by using the calibration
198 curve of phloretin-2'-*O*-glucoside, dihydroxyphenylpropionic acid sulphate by using the
199 calibration curve of 3-(2',4'-dihydroxyphenyl)propionic acid, and hydroxyphenyl-γ-
200 valerolactone by using the calibration curve of epicatechin. Catechol sulphate and methyl
201 catechol sulphate were quantified with their own calibration curves, and catechol glucuronide
202 by using the calibration curve of catechol-4-*O*-sulphate.

2.6. Validation procedure

The instrumental quality parameters of the developed methods, such as linearity, precision, accuracy, detection limits (LODs), and quantification limits (LOQs), as well as the extraction recovery (%R) and matrix effect (%ME) for the determination of the main phenolic metabolites in blood and plasma samples by DBS cards, and plasma samples by μ SPE, were determined by spiking blank biological samples (venous blood and plasma samples obtained under fasting conditions) with known concentrations of standard phenolic compounds. Calibration curves were prepared with venous blood, since it was not possible to obtain large volumes of blank capillary blood. These instrumental quality parameters, as well as the %R and %ME, were determined as reported in our previous study [14], and the results obtained are shown in **Table 2**.

2.7. Statistical analysis

The quantitative data were analyzed by Student's *t*-test in order to determine significant differences between mean values of the concentration of the main circulating apple phenolic metabolites in: 1) the capillary and venous blood at different post-intake times, 2) the venous blood (venipuncture) and plasma samples (venipuncture) at different times, and 3) the venous plasma analysed by DBS cards and by μ SPE at different times. Significant differences were considered at the level of $p < 0.05$. All the statistical analyses were carried out using STATGRAPHICS Plus 5.1 (Manugistics Inc., Rockville, MD, USA).

3. Results and Discussion

3.1. Optimization of DBS technique for phenolic metabolite analysis

This work was based on our previous studies, where phenolic metabolites were determined in plasma or blood samples after the acute intake of strawberry tree fruit [8] and olive oil phenolic extract [9]. In these previous studies, 20 μ L of venous blood or plasma were spotted onto one pre-marked circle on the DBS and 7 disks of 2 mm diameter were punched out from the card using 100 μ L of methanol/Milli-Q water (50/50, v/v) for the phenolic

230 extraction. Under these experimental conditions, only the most abundant circulating phenol
231 metabolites were detected. In the present study, in order to enhance the method sensitivity,
232 different conditions were tested to improve the extraction and increase the pre-concentration
233 of the analytes. We also aimed to explore a strategy to quantify the phenolic metabolites
234 directly by depositing blood droplets on DBS card in order to simplify the process.

235 The factors studied were: (i) the blood volume spotted on the pre-marked circle (from
236 20 to 50 μL), (ii) the number of disks punched out from the card (from 7 disks to the entire
237 pre-marked circle) and the number of the pre-marked circles (1 or 2), (iii) the nature of the
238 extraction solvent (methanol, methanol/Milli-Q water (50/50, v/v), and acetonitrile), and its
239 volume (from 100 to 200 μL), and (iv) the extraction time with vortex (from 5 to 30 min).

240 In the present study, six different phenolic metabolites derived from phase II and
241 microbial metabolism were detected in both the blood and plasma human samples.
242 Specifically, the main metabolites detected were phloretin glucuronide,
243 dihydroxyphenylpropionic acid sulphate, (methyl) catechol sulphate, catechol glucuronide,
244 and hydroxyphenyl- γ -valerolactone glucuronide. Therefore, to optimize the method different
245 phenol standards as catechol-4-*O*-sulphate, 4-methyl catechol sulphate, 3-(2',4'-dihydroxy-
246 phenyl)propionic acid, epicatechin and phloretin-2'-*O*-glucoside were spiked at known
247 concentrations into a pooled venous human blood obtained under fasting conditions.

248 3.1.1 *Blood volume spotted on the pre-marked circle*

249 Four different blood volumes applied to the cards were tested (20, 30, 40 and 50 μL)
250 (data not show). In our previous study, volumes from 5 to 20 μL were tested and a greater
251 instrumental response of the phenolic standards was reported as the blood volume increased
252 [9]. In the present study, 30 μL was selected as the optimum volume observing that, with this
253 volume, one pre-marked circle was entirely soaked to its edge with all volunteers' blood
254 samples. This fact denoted that the viscosity of the blood from all volunteers was similar as
255 were its spreading properties on the DBS cards, thus indicating a similar hematocrit.

1 256 When droplet of capillary blood is directly deposited on the filter paper, the volume of
2
3 257 this blood cannot be precisely controlled and inaccuracies in quantification values can be
4
5 258 obtained due to differences in hematocrit. In the literature, different strategies to overcome
6
7 259 this drawback have been proposed, such as the use of volumetric absorptive microsampling
8
9 260 (VAMS) [15] or the photometric measurement of the protein content [16]. In the present
10
11 261 study, a simplified strategy to quantify the phenolic metabolites was tested, assuming a linear
12
13 262 relation between volume of blood applied and the area of the pre-marked DBS circle. In this
14
15 263 sense, we asked volunteers to soak the entire surface of the pre-marked circles with capillary
16
17 264 blood, estimating that the entire surface of one pre-marked circle contained 30 μL of capillary
18
19 265 blood, as observed when a fixed volume of the volunteers' blood was dispensed on to the
20
21 266 DBS.
22
23

24 267 *3.1.2 Spot punch surface*

25
26
27 268 In the present study, the fact of punching out the maxim number of disks (eight 2-mm
28
29 269 diameter disks) or the entire surface of the pre-marked circle was tested and the instrumental
30
31 270 response of all the phenolic compounds studied increased slightly when the entire pre-marked
32
33 271 circle was analyzed (data not shown). Moreover, in a previous study, it was reported that the
34
35 272 whole spot approach can effectively avoid any hematocrit effect in the analysis of a specific
36
37 273 drug (apixaban) in human DBS samples compared to a partial spot-center punch [17].
38
39

40 274 Moreover, the fact of analyzing two instead of one pre-marked circles with reduced
41
42 275 elution solvent volume was also tested, and a major pre-concentration effect of the target
43
44 276 compounds was observed.
45

46 277 *3.1.3 Extraction solvent volume and nature*

47
48
49 278 The tested elution volumes were 100, 150, and 200 μL . The use of 100 μL was discarded
50
51 279 because this was not large enough to cover two entire pre-marked circles. Volumes of 150 and
52
53 280 200 μL allowed the phenolics to be extracted with good %R, but with 150 μL , a higher pre-
54
55 281 concentration rate was obtained and the %R and % ME were not significantly affected (data
56
57
58
59
60

not shown). Different elution solvents were also tested in order to obtain the maximum sensitivity (peak efficiency or narrow peaks) and maximum extraction recovery (%R). Among all the elution solvents tested, methanol/Milli-Q water (50/50, v/v) was the optimum in terms of peak efficiency, and %R, and therefore this elution solvent was chosen.

3.1.4 Extraction time

Firstly, the extraction time (vortex) of the disks with the elution solvent was optimized, and 5, 10, 20 and 30 min were tested. It was observed that the extraction of the main phenolic metabolites increased with the extraction time and this fact was observed until 20 min with no differences between 20 and 30 min, so 20 min was selected as the optimum time (data not shown). So, the optimum pretreatment conditions with DBS cards were defined as: 30 μ L of venous blood in each pre-marked circle, punching out the entire surface of two pre-marked circles, 150 μ L of methanol/Milli-Q water (50/50, v/v) solution as the extraction solvent and 20 min as the extraction time (vortex) (**Figure 1A**). The same conditions were used for the venous plasma and capillary blood. Under these experimental conditions, the %R of all the studied phenolics was above 75% and the matrix effect (ME%) was lower than 18% (**Table 2**).

3.2. μ SPE phenolic metabolite analysis

μ SPE was also applied for the analysis of the main circulating phenolic metabolites in venous plasma samples as it is the most common sample pretreatment used in our previous studies, and the obtained results were compared to those achieved from plasma by using DBS cards. The methodology used is the previous reported in our studies for the determination of epicatechin [12], and dihydroxyphenylpropionic acid and (methyl) catechol sulfate [13] in plasma samples.

3.3. Analytical methods validation

The instrumental quality parameters of the developed methods using DBS cards for the analysis of the venous blood and plasma samples, and μ SPE for the analysis of plasma

1 308 samples, are shown in **Table 2**. In order to carry out these studies, catechol-4-*O*-sulphate, 4-
2
3 309 methyl catechol sulphate, 3-(2',4'-dihydroxyphenyl)propionic acid, epicatechin and phloretin-
4
5 310 2'-*O*-glucoside were spiked into blank venous blood samples and blank plasma samples at
6
7 311 different known concentrations. The linearity range was from 0.04 to 10 μM for venous
8
9 312 blood, and 0.03 to 10 μM for plasma samples when DBS cards were used; and 0.0008 to 10
10
11 313 μM for plasma samples when μSPE was used.

14 314 The calibration curves (based on the integrated peak area) were calculated by using five
15
16 315 points at different concentration levels, and each concentration was injected three times. The
17
18 316 determination coefficient (R^2) of the calibration curves was higher than 0.993. The precision
19
20 317 of the analytical method (reproducibility) were determined by the relative standard deviation
21
22 318 (% RSD) in terms of concentration, and these were calculated at three concentration levels,
23
24 319 these being 5, 0.1 and 0.01 μM for the analysis of venous blood and plasma samples (**Table**
25
26 320 **2**). For all the phenolic compounds the %RSDs were lower than 10% in both DBS cards and
27
28 321 μSPE methods. The accuracy was calculated from the ratio between the concentration found
29
30 322 for the standard phenolic compounds studied compared with the spiked concentration. This
31
32 323 quotient was then multiplied by 100. This quality parameter was also studied at three
33
34 324 concentration levels, the same as for the RSD%, and these ranged from 97% to 103%.

38 325 The LODs and LOQs were calculated using the signal-to-noise ratio criterion of 3 and
39
40 326 10, respectively. The respective values were in the 15-30 and 45-95 nM ranges for venous
41
42 327 blood samples, and the 15-25 and 34-75 nM ranges for plasma samples when DBS cards were
43
44 328 used. These results were 10-fold lower to our previous study where olive oil phenol
45
46 329 metabolites were determined in blood samples using DBS cards [9]. So, the fact of punching
47
48 330 two entire pre-marked circles and decrease the elution solvent volume, improved the
49
50 331 sensitivity of the method.

53 332 The LODs and LOQs in the analysis of plasma samples by μSPE were 0.3-20 and 0.8-50
54
55 333 nM, respectively. It is important to highlight the lower LODs and LOQs in comparison with

1 334 DBS cards. This fact could be explained by the analyte pre-concentration (3.5-fold) that is
2
3 335 performed in μ SPE (350 μ L of plasma are loaded and 100 μ L elution solvent are used to
4
5 336 elute). Nevertheless when DBS cards are used, the analytes are diluted (2.5-fold). So, 60 μ L
6
7 337 of biological samples are directly deposited in the circles of the DBS card (2 circles with 30
8
9 338 μ L each one) and then 150 μ L of extraction solvent are used to analyze the compounds of
10
11
12 339 interest.

13
14 340 The %R for the analysis of the studied phenolics in venous blood and plasma samples (in
15
16 341 both DBS cards and μ SPE) were similar and these were higher than 75 % (**Table 2**), except
17
18 342 for (methyl) catechol sulphate in μ SPE, being between 59-63 %. The %ME for the analysis of
19
20 343 the studied phenolics in these biological samples was lower than 15 %, being lower in the
21
22 344 μ SPE pre-treatment (**Table 2**).

23 345 **3.4. Capillary blood versus venous blood in DBS cards**

24
25
26 346 **Figure 2** shows the time-course of the main generated phenolic metabolites determined
27
28 347 in capillary blood, venous blood and venous plasma using DBS cards at different time points
29
30 348 (0-24 h) after the acute intake of red-fleshed apple snack. When comparing mean values of
31
32 349 capillary blood versus venous blood, no significant differences ($p > 0.05$) were observed in
33
34 350 any metabolite or at any time point. Previous studies with drugs found concentrations about
35
36 351 1.7 times higher in capillary than venous blood [18], but these differences are dependent on
37
38 352 the characteristics of particular compounds, so case-to-case evaluation is necessary. The
39
40 353 results of the present study indicate that in the case of apple phenolic metabolite, values do
41
42 354 not differ significantly between venous blood and capillary blood.

43
44
45 355 Regarding the time-course data, the maximum concentration of the circulating
46
47 356 metabolites phloretin glucuronide and dihydroxyphenylpropionic acid sulphate was found
48
49 357 between 2 and 4 h, indicating their metabolic transformation in the small intestine and liver
50
51 358 (**Figure 2**). The other metabolites (catechol sulphate, methyl catechol sulphate, catechol
52
53 359 glucuronide, and hydroxyphenyl- γ -valerolactone glucuronide) appeared to have their

1 360 maximum concentrations 12 h after consumption of the apple snack, indicating that they
2
3 361 could be products of the gut microbiota catabolism in the colon.
4

5 362 One of the most important advantages of using DBS cards reported in the present study is
6
7 363 the possibility of analyzing more post-intake time points by self-sampling compared to
8
9 364 venipuncture. Particularly, the possibility of taking sample at 12 h enabled the detection and
10
11 365 quantification of two colonic metabolites (catechol glucuronide, and hydroxyphenyl- γ -
12
13 366 valerolactone glucuronide) (**Figure 2**). These results indicate the importance of collecting
14
15 367 these time points to gain deeper insights into the in-vivo distribution of metabolites produced
16
17 368 by gut microbiota.
18
19

20 369 **3.5. Venous blood versus venous plasma samples in DBS cards**

21
22 370 The concentration values of the phenolic compounds determined in venous blood
23
24 371 samples after the acute intake of the red apple snack were also compared to those obtained for
25
26 372 the analysis of their corresponding plasma samples and the results showed no significant
27
28 373 differences in any metabolite at any time point (**Figure 2**).
29
30

31 374 Pharmacokinetic studies are commonly carried out focusing on the levels of phenolic
32
33 375 metabolites in plasma or serum. However, in the case of some polyphenols their affinity for
34
35 376 human blood cells has been observed. For instance, quercetin [19-20] and resveratrol [21] are
36
37 377 known to partition into blood cells, associating with cell membranes, haemoglobin and other
38
39 378 proteins. The binding of low concentrations of polyphenols to erythrocytes was also reported
40
41 379 for caffeic acid, taxifolin, and ferulic acid in a human study [6] and hydroxytyrosol phase-II
42
43 380 metabolites in a rat model [5]. In a recent study it was also reported a differential distribution
44
45 381 of phenolic compounds between serum and blood cells depending on the characteristics of
46
47 382 particular polyphenols [22], confirming that case-to-case evaluation is necessary.
48
49

50
51 383 As shown in **Figure 2**, in the case of phenolic metabolites derived mainly from phenolic
52
53 384 acids and anthocyanins from apple, plasma levels appear to be lower than blood
54
55
56
57
58
59
60

1 385 concentration. However, no significant differences were found between blood and plasma,
2
3 386 probably due to the large interindividual variability in the phenolic metabolism.

4
5 387 Based on our results and also considering previous studies, the application of DBS cards
6
7 388 with blood as the mainstay matrix might yield valuable information as a practical alternative
8
9 389 to classic plasma analysis to determine the in-vivo human absorption of phenolic metabolites.

10 390 **3.6. DBS cards versus μ SPE for venous plasma samples**

11
12
13
14 391 μ SPE is the sample pre-treatment technique most commonly used to extract phenolic
15
16 392 metabolites from plasma samples. However, this technique requires venipuncture to obtain a
17
18 393 sufficient volume of blood sample and subsequently of plasma sample. In order to evaluate
19
20 394 whether DBS cards can be an alternative strategy to μ SPE, venous plasma samples were
21
22 395 analysed by using both methods and the obtained results were compared. **Table 3** shows the
23
24 396 average concentrations from the ten healthy volunteers of the main phenolic metabolites and
25
26 397 no significant differences were detected among both methods. Although the sensitivity (LODs
27
28 398 and LOQs) of DBS cards technique was lower than μ SPE, the average concentrations of the
29
30 399 main phenolic metabolites detected in plasma did not significantly differ between the two
31
32 400 sample pre-treatment techniques. Therefore, we conclude that DBS cards is a suitable strategy
33
34 401 for the analysis of circulating phenolic metabolites in human interventional studies, and also
35
36 402 for urine analysis as we reported previously [12].
37
38
39

40 403

41 404 **4. Conclusions**

42
43
44 405 A method based on DBS cards combined with liquid chromatography (UPLC-
45
46 406 MS/MS) was developed and validated for the determination of phenolic metabolites in human
47
48 407 blood and plasma samples. DBS cards has been reported as a rapid and easy blood-sampling
49
50 408 strategy to determine the main circulating phenolic metabolites after an acute intake of red-
51
52 409 fleshed apple snack. The comparison of capillary and venous sampling and also the
53
54
55
56
57
58
59
60

1 410 assessment of the differences between whole blood and plasma samples showed no significant
2
3 411 differences. In addition, there were no significant differences among DBS cards and μ SPE.
4

5 412 The self-sampling of blood by the volunteers following simple instructions, allowed
6
7 413 more times points to be collected during postprandial period, especially those late time points
8
9 414 (12 h) to assess the colonic metabolism of phenolic compounds, which are normally missing
10
11 415 with venipuncture. Our study reveal that finger-prick blood sampling based on DBS cards
12
13 416 appears to be a suitable alternative to the classic invasive venipuncture for determining
14
15 417 phenolic metabolites, including colonic fermentation catabolites, in human polyphenol
16
17 418 bioavailability and pharmacokinetic studies.
18
19

20 419

21 420 **Acknowledgments**

22
23
24 421 This study was supported by the Spanish Ministry of Industry, Economy and Competitiveness
25
26 422 through the AGL2016-76943-C2-1-R project (co-funded by the European Social Fund,
27
28 423 European Union); by the Spanish Ministry of Industry, Economy and Competitiveness
29
30 424 through the I. A. Ludwig postdoctoral research contract (Juan de la Cierva, FJCI-2014-
31
32 425 20689); and by the University of Lleida through the Silvia Yuste grant. In addition, the
33
34 426 authors are grateful to NUFRI (Mollerussa, Lleida, Catalonia, Spain) for providing the apples.
35
36 427 Ú.C. has a PERIS post-doctoral grant (SLT002/16/00239; Catalunya, Spain). NFOC-Salut
37
38 428 group is a consolidated research group of Generalitat de Catalunya, Spain (2017 SGR 522).
39

40 429 The authors have declared no conflicts of interest.
41

42 430

43 431 **References**

44
45
46
47 432 1. Wagner, M., Tonoli, D., Varesio, E., Hopfgartner, G. The use of mass spectrometry to
48
49 433 analyze dried blood spot samples. *Mass Spectrometry Reviews* 2016, 35, 361-438.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 434 2. Evans, C., Arnold, M., Bryan, P., Duggan, J., et al. Implementing Dried Blood Spot
435 Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ
436 Consortium Microsampling Working Group. *AAPS J.* 2015, 17(2), 292–300.
 - 437 3. Hinderling, P.H. Red Blood Cells: A Neglected Compartment in Pharmacokinetics and
438 Pharmacodynamics. *Pharmacological Reviews* 1997, 49 (3), 279-295.
 - 439 4. Biasutto, L., Marotta, E., Garbisa, S., Zoratti, M. et al. (2010). Determination of Quercetin
440 and Resveratrol in Whole Blood—Implications for Bioavailability Studies. *Molecules*,
441 2010, 15 (9), 6570-6579
 - 442 5. Rubió, L., Serra, A., Macià, A., Piñol, C. et al. In vivo distribution and deconjugation of
443 hydroxytyrosol phase II metabolites in red blood cells: A potential new target for
444 hydroxytyrosol. *Journal of Functional Foods* 2014, 10 (1), 139-143
 - 445 6. Kurlbaum, M., Mülle, M., Högger, P. Facilitated Uptake of a Bioactive Metabolite of
446 Maritime Pine Bark Extract (Pycnogenol) into Human Erythrocytes. *PLoS ONE* 2013, 8
447 (4), Article number e63197.
 - 448 7. Antunes, M.V., Charao, M.F., Linden R. Dried blood spots analysis with mass
449 spectrometry: Potentials and pitfalls in therapeutic drug monitoring. *Clinical Biochemistry*
450 2016, 49 (13-14), 1035-1046.
 - 451 8. Mosele, J.I., Macià, A., Motilva, M.J. Understanding of human metabolic pathways of
452 different sub-classes of phenols from *Arbutus unedo* fruit after an acute intake. *Food &*
453 *Function* 2016, 7, 1700-1710.
 - 454 9. López de las Hazas, Motilva, M.J., Piñol, C., Macià, A. Application of dried blood spot
455 cards to determine olive oil phenols (hydroxytyrosol metabolites) in human blood. *Talanta*
456 2016, 159, 189-193.
 - 457 10. Pimpao, R.C., Ventura, M.R., Ferreira, R.B., Williamson, G., et al. Phenolic sulfates as
458 new and highly abundant metabolites in human plasma after ingestion of a mixed berry
459 fruit purée. *British Journal of Nutrition* 2015, 113, 454-463.

- 1 460 11. Bars-Cortina, D., Macià, A., Iglesias, I., Romero, et al. Phytochemical profiles of new
2
3 461 red-fleshed Apple varieties compared with traditional and new white-fleshed varieties.
4
5 462 *Journal of Agricultural Food Chemistry* 2017, 65, 1684-1696.
6
7
8 463 12. Martí, M.P., Pantaleón, A., Rozek, A., Soler, A., Valls, J., Macià, A., Romero, M.P.,
9
10 464 Motilva, M.J. Rapid analysis of procyanidins and anthocyanins in plasma by microelution
11
12 465 SPE and ultra-HPLC. *Journal of Separation Science* 2010, 33, 2841-2853.
13
14
15 466 13. Perez-Ternero, C., Macià, A., Alvarez de Sotomayor, M., Parrado, J., Motilva, M.J.,
16
17 467 Herrea, M.D. Bioavailability of the ferulic acid-derived phenolic compounds of a rice bran
18
19 468 enzymatic extract and their activity against superoxide production. *Food & Function* 2017,
20
21 469 8 2165-2174.
22
23
24 470 14. Serra, A., Rubió, L., Macià, A., Valls, R.M., et al. Application of dried spot cards as a
25
26 471 rapid sample treatment method for determining hydroxytyrosol metabolites in human urine
27
28 472 samples. Comparison with microelution solid-phase extraction. *Analytical and*
29
30 473 *Bioanalytical Chemistry* 2013, 405, 9179-9192.
31
32
33 474 15. Kok, M.G.M., Millet, M. Volumetric absorptive micro-sampling: Current advances and
34
35 475 applications. *Journal of Pharmaceutical and Biomedical Analysis* 2018, 147, 288-296.
36
37 476 16. Riley, R.T., Showker, J.L., Lee, C.M., Zipperer, C.E., et al. A blood spot method for
38
39 477 detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice
40
41 478 and humans. *Food additives & Contaminants* 2015, 32, 934-949
42
43
44 479 17. Zhen, N., Yu, L., Ji, Q.C., Mangus, H., et al. "Center punch" and "whole spot"
45
46 480 bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS. *Journal*
47
48 481 *of Chromatography B* 2015, 988, 66-74.
49
50
51 482 18. E.A. Ashley, K. Stepniewska, N. Lindegardh, A. Annerberg, J. et al. Comparison of
52
53 483 plasma, venous and capillary blood levels of piperazine in patients with uncomplicated
54
55 484 falciparum malaria. *European Journal of Clinical Pharmacology* 2010, 66 (7), 705-712.
56
57
58
59
60

- 1 485 19. Chandhuri, S.; Banerjee, A.; Basu, K.; Sengupta, B.; Sengupta, P.K. Interaction of
2
3 486 flavonoids with red blood cell membrane lipids and proteins: antioxidant and
4
5 487 antihemolytic effects. *International Journal of Biological Macromolecules* 2007, 41, 42-
6
7 488 48.
- 9
10 489 20. Fiorani, M.; Accorsi, A.; Cantoni, O. Human red blood cells as a natural flavonoid
11
12 490 reservoir. *Free Radical Research* 2003, 37, 1331-1338.
- 14
15 491 21. Blache, D.; Rustan, I.; Durand, P.; Lesgards, G.; Loreau, N. Gas chromatographic analysis
16
17 492 of resveratrol in plasma, lipoproteins and cells after in vitro incubations. *Journal of*
18
19 493 *Chromatography B* 1997, 702, 103-110.
- 21
22 494 22. Mulek M., Seefried L., Genest F., Hogger P. Distribution of constituents and metabolites
23
24 495 of maritime pine bark extract (Pycnogenol®) into serum, blood cells, and synovial fluid of
25
26 496 patients with severe osteoarthritis: A randomized controlled trial. *Nutrients* 2017, 9 (5) ,
27
28 497 art. no. 443.

31
32 498
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 499 **Figure Captions**


2
3
4 500 **Figure 1.** Schematic representation of the sample pre-treatment protocol developed based on
5
6 501 dried blood spot cards and microElution solid-phase extraction.

7
8 502

9
10 503 **Figure 2.** Time-course of the main phenolic metabolites determined in capillary blood,
11 504 venous blood and venous plasma samples by DBS and UPLC-MS/MS after the acute intake
12 505 of red-fleshed apple snack.

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review



UPLC-MS/MS analysis
Phenolic metabolites pharmacokinetics




Table 1. Phenolic compounds ingested in a dose of 80 g of red-fleshed apple snack.

Phenolic compound	mg/80 g red-fleshed apple snack
Cyanidin galactoside	39.7 ± 1.0
Cyanidin arabinoside	2.60 ± 0.24
Total Anthocyanins	42.3 ± 1.18
Protocatechuic acid	1.71 ± 1.06
Coumaric acid hexoside	0.77 ± 0.11
Ferulic acid hexoside	2.12 ± 0.26
Vanillic acid hexoside	4.28 ± 0.11
Chlorogenic acid	79.1 ± 2.75
Total Phenolic acids	88.03 ± 3.34
Epicatechin	5.58 ± 0.78
Dimer	6.92 ± 0.29
Trimer	1.30 ± 0.12
Total Flavan-3-ols	13.8 ± 1.18
Quercetin arabinoside	3.67 ± 0.45
Quercetin rhamnoside	9.26 ± 0.94
Quercetin glucoside	4.41 ± 0.57
Total Flavonols	17.3 ± 1.97
Eriodictyol hexoside	0.42 ± 0.02
Total Flavanones	0.42 ± 0.02
Phloretin glucoside	21.7 ± 2.54
Phloretin xylosyl glucoside	11.7 ± 0.52
Hydroxyphloretin xylosil glucoside	0.32 ± 0.03
Total Dihydrochalcones	33.7 ± 3.08
Total Phenols	195 ± 9.60

Table 2. Instrumental quality parameters for the analysis by UPLC-MS/MS of the studied phenolic compounds in spiked venous blood and plasma samples by DBS cards, and venous plasma samples by μ SPE.


Phenolic compound	RT (min)	%R	%ME	Linearity (μ M)	%RSD ($n=3$), inter-day			Accuracy (%), $n=3$, (0.1 μ M)	LOQ (nM)	LOD (nM)
					5 μ M	0.1 μ M	0.01 μ M			
DBS cards										
<i>Venous blood</i>										
Catechol-4- <i>O</i> -sulphate	3.01	85 \pm 0.1	4.52 \pm 0.1	0.09 - 10	5.1	6.4	8.2	97	90	30
4-Methyl catechol sulphate	4.87	82 \pm 0.3	9.50 \pm 0.1	0.08 - 10	4.3	5.9	8.6	98	85	30
3-(2',4'-dihydroxyphenyl)propionic acid	5.36	75 \pm 0.2	7.91 \pm 0.1	0.08 - 10	6.2	7.5	8.5	101	85	30
Epicatechin	7.05	90 \pm 0.1	-5.83 \pm 0.2	0.09 - 10	5.9	6.8	8.8	102	95	30
Phloretin-2'- <i>O</i> -glucoside	16.4	80 \pm 0.2	-18.5 \pm 0.1	0.04 - 10	7.8	8.9	10	101	45	15
<i>Venous plasma</i>										
Catechol-4- <i>O</i> -sulphate	3.01	83 \pm 0.1	5.68 \pm 0.1	0.07 - 10	4.8	6.1	8.3	103	70	25
4-Methyl catechol sulphate	4.87	80 \pm 0.2	10.3 \pm 0.2	0.07 - 10	4.6	6.4	8.3	101	73	25
3-(2',4'-dihydroxyphenyl)propionic acid	5.36	80 \pm 0.1	-6.82 \pm 0.1	0.07 - 10	6.6	7.3	8.8	100	75	25
Epicatechin	7.05	88 \pm 0.2	-16.7 \pm 0.2	0.05 - 10	5.8	7.4	9.4	99	50	20
Phloretin-2'- <i>O</i> -glucoside	16.4	80 \pm 0.1	-17.2 \pm 0.1	0.03 - 10	7.8	8.9	10	101	35	15
μSPE										
<i>Venous plasma</i>										
Catechol-4- <i>O</i> -sulphate	3.01	63 \pm 0.1	-4.60 \pm 0.1	0.0008 - 10	5.2	5.9	8.2	102	0.8	0.3
4-Methyl catechol sulphate	4.87	59 \pm 0.1	-6.71 \pm 0.2	0.001 - 10	3.9	5.2	8.0	100	1	0.3
3-(2',4'-dihydroxyphenyl)propionic acid	5.36	95 \pm 0.2	-5.35 \pm 0.1	0.007 - 10	5.8	6.2	8.1	98	7	2
Epicatechin	7.05	98 \pm 0.2	-6.39 \pm 0.2	0.05 - 10	5.4	6.8	8.5	101	50	20
Phloretin-2'- <i>O</i> -glucoside	16.4	90 \pm 0.1	-9.99 \pm 0.1	0.003 - 10	7.0	8.0	9.7	99	3	1

Table 3. Mean concentration of the generated phenolic metabolites (μM or $\text{nM} \pm$ standard deviation) in plasma samples, analysed by DBS cards and μSPE combined with UPLC-MS/MS, after the acute intake of a red-fleshed apple snack at different time points.

	0 h	0.5 h	1 h	2 h	4 h	6 h	24 h
Phloretin glucuronide (nM)							
DBS	n.d.	26.9 \pm 9.46	32.5 \pm 9.42	39.4 \pm 16.8	27.6 \pm 11.2	9.55 \pm 15.4	n.d.
μSPE	n.d.	28.2 \pm 11.2	42.9 \pm 8.36	53.8 \pm 16.2	54.0 \pm 34.6	23.6 \pm 16.4	n.d.
Dihydroxyphenylpropionic acid sulphate (nM)							
DBS	n.d.	17.3 \pm 14.6	12.5 \pm 19.4	19.5 \pm 43.2	70.3 \pm 105.6	50.6 \pm 68.2	n.d.
μSPE	n.d.	14.4 \pm 18.6	9.87 \pm 10.2	10.6 \pm 9.6	53.9 \pm 63.1	33.0 \pm 40.7	n.d.
Catechol sulphate (μM)							
DBS	0.22 \pm 0.19	0.30 \pm 0.28	0.27 \pm 0.22	0.28 \pm 0.21	0.40 \pm 0.33	0.50 \pm 0.23	0.20 \pm 0.05
μSPE	0.42 \pm 0.37	0.45 \pm 0.36	0.42 \pm 0.37	0.42 \pm 0.29	0.55 \pm 0.40	0.83 \pm 0.71	0.29 \pm 0.12
Methyl catechol sulphate (μM)							
DBS	0.19 \pm 0.21	0.27 \pm 0.25	0.28 \pm 0.27	0.27 \pm 0.25	0.28 \pm 0.25	0.32 \pm 0.31	0.42 \pm 0.33
μSPE	0.41 \pm 0.51	0.45 \pm 0.47	0.45 \pm 0.50	0.40 \pm 0.46	0.35 \pm 0.31	0.47 \pm 0.44	0.47 \pm 0.31

Catechol glucuronide and hydroxyphenyl- γ -valerolactone glucuronide were not detected in plasma samples at the collected time points.

n.d. not detected



◆ capillary blood ■ venous blood ▲ venous plasma

